These awards support any stage of the translational research and development pathway, including the clinical development of laboratory-validated technologies or interventions.
Award: No upper funding limit
Opens: 20th Oct 2021
Closes: 8th Dec 2021
i4i Product Development Awards (PDA) support translational research and development of medical devices, in vitro diagnostics and high-impact patient-focused digital health technologies for ultimate NHS use. The research proposals may address any disease or health area, provided there is a clear unmet clinical need. There is no upper funding limit for Product Development Awards, but costs must be fully justified.
i4i funds collaborative R&D projects in medtech SMEs, universities and the NHS that have demonstrated proof-of-principle and have a clear pathway towards adoption and commercialisation. The aim is to de-risk projects, making them attractive to follow-on funders and investors.
i4i competitions are based on a two stage application process. This is for Stage 1.
For PDA Call 23 – Stage 2 will launch 17th February 2022 and is by invitation only.
For more information on NIHR i4i competitions, please click here.
Projects must have already demonstrated ‘proof of principle’. Applicants are expected to have generated experimental data to support the case for further development and illustrate technical feasibility. Early stage research or discovery science is not fundable.
Work packages must not include animal studies or work on animal tissues. If animal studies are required as part of the project, it is expected that applicants will seek parallel funding to cover such studies, details of which can be provided in the application form.